Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.56 HKD
Change Today -0.03 / -0.84%
Volume 1.6M
503 On Other Exchanges
Symbol
Exchange
Berlin
Hong Kong
As of 4:01 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

lansen pharmaceutical holdin (503) Snapshot

Open
$3.59
Previous Close
$3.59
Day High
$3.62
Day Low
$3.51
52 Week High
09/19/14 - $4.15
52 Week Low
02/12/15 - $2.28
Market Cap
1.5B
Average Volume 10 Days
1.8M
EPS TTM
$0.03
Shares Outstanding
415.0M
EX-Date
06/12/15
P/E TM
13.5x
Dividend
$0.18
Dividend Yield
4.63%
Current Stock Chart for LANSEN PHARMACEUTICAL HOLDIN (503)

Related News

No related news articles were found.

lansen pharmaceutical holdin (503) Related Businessweek News

No Related Businessweek News Found

lansen pharmaceutical holdin (503) Details

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in the People’s Republic of China and internationally. It operates in Specialty Pharmaceuticals, Plant Extract and Healthcare Products, and Other Pharmaceuticals segments. The company’s core rheumatic specialty prescription western pharmaceuticals comprise Pafulin, which includes total glucosides of white peony capsules; Tuoshu, a leflunomide tablet; and MMF. It also offers other pharmaceuticals that include Bazhen Keli, a gynecological product; Yinxingye Pian, Paracetamol orally disintegrating tablets, and Dingpeng Rugao; and Huperzine A capsules, Chanfukang Keli, Ganda Pian, Xinnaojian Jiaonang, Runing Pian, Jian'er Qingjie Ye, and Xiao'er Jianwei Tangjiang, as well as Chinese medicine extracts and healthcare products. In addition, the company distributes human-like collagen dressing products, which are used for the suppression and mitigation of skin inflammation responses caused by various reasons, such as dermatitis, sensitive skin, acne, and laser therapy under the Kefumei brand in China. The company was founded in 2001 and is headquartered in Ningbo, the People’s Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Holdings Limited.

880 Employees
Last Reported Date: 04/15/15
Founded in 2001

lansen pharmaceutical holdin (503) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $179.0K
Compensation as of Fiscal Year 2013.

lansen pharmaceutical holdin (503) Key Developments

Lansen Pharmaceutical Holdings Co., Ltd Recommends Final Dividend for the Year Ended December 31, 2014 Payable on or Around June 30, 2015

Lansen Pharmaceutical Holdings Co. Ltd. announced that an annual general meeting will be held on June 3, 2015, to approve the recommended final dividend of 8.74 cents per share of USD 0.01 each in the capital of the company out of the company's share premium account for the year ended December 31, 2014. Subject to the approval by shareholders of the company at the annual general meeting, the final dividend will be distributed in Hong Kong dollars. The register of members of the company will be closed from June 16, 2015 to June 18, 2015, both dates inclusive, during which period no transfer of shares will be registered. In order to qualify for the entitlement to the final dividend, all transfers, accompanied by the relevant share certificates, must be lodged for registration with the company's share registrar in Hong Kong, Tricor Investor Services Limited not later than 4.30 p.m. on June 15, 2015. The final dividend will be payable on or around June 30, 2015.

Lansen Pharmaceutical Holdings Co., Ltd Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Lansen Pharmaceutical Holdings Co. Ltd. announced audited consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenue of $116,817,000 against $95,074,000 a year ago. Profit from operations was $18,922,000 against $15,144,000 a year ago. Profit before income tax was $18,068,000 against $15,081,000 a year ago. Profit attributable to owners of the company was $13,980,000 or 3.4 cents per basic and diluted share against $11,691,000 or 2.8 cents per basic and diluted share a year ago.

Lansen Pharmaceutical Holdings Co., Ltd to Report Fiscal Year 2014 Results on Mar 27, 2015

Lansen Pharmaceutical Holdings Co., Ltd announced that they will report fiscal year 2014 results on Mar 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
503:HK $3.56 HKD -0.03

503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 503.
View Industry Companies
 

Industry Analysis

503

Industry Average

Valuation 503 Industry Range
Price/Earnings 13.7x
Price/Sales 1.6x
Price/Book 1.7x
Price/Cash Flow 13.7x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANSEN PHARMACEUTICAL HOLDIN, please visit www.lansen.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.